Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials
Authors
Keywords
-
Journal
CIRCULATION
Volume 145, Issue 19, Pages 1460-1470
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2022-04-09
DOI
10.1161/circulationaha.121.057736
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Changes in Cardiovascular Biomarkers Associated With the Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes
- (2021) Patrick R. Lawler et al. DIABETES CARE
- Ambulatory Treatments for RAAS Inhibitor–Related Hyperkalemia and the 1-Year Risk of Recurrence
- (2021) Gregory L. Hundemer et al. Clinical Journal of the American Society of Nephrology
- Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists
- (2021) Li Shen et al. JACC-Heart Failure
- Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure
- (2021) João Pedro Ferreira et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
- (2021) Brendon L Neuen et al. EUROPEAN HEART JOURNAL
- Chronic kidney disease
- (2021) Kamyar Kalantar-Zadeh et al. LANCET
- Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
- (2021) Peter Rossing et al. Kidney International Reports
- Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials
- (2020) Muthiah Vaduganathan et al. LANCET
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
- (2020) Faiez Zannad et al. LANCET
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
- (2020) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
- (2020) Darren K. McGuire et al. JAMA Cardiology
- Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial
- (2020) Rosalie A. Scholtes et al. DIABETES CARE
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
- (2019) Brendon L Neuen et al. Lancet Diabetes & Endocrinology
- Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
- (2019) Catherine M. Clase et al. KIDNEY INTERNATIONAL
- 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETES CARE
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- Risk of hyperkalemia from renin–angiotensin–aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population
- (2019) James B Wetmore et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epidemiology of hyperkalemia: an update
- (2016) Csaba P. Kovesdy Kidney International Supplements
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulation of Potassium Homeostasis
- (2014) B. F. Palmer Clinical Journal of the American Society of Nephrology
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- Mechanisms in Hyperkalemic Renal Tubular Acidosis
- (2009) F. E. Karet JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started